Audio Recap: Switching With Suppression
Answering the Questions on Switching ART With Virologic Suppression

Released: October 19, 2022

Expiration: October 18, 2023

Tristan J. Barber
Tristan J. Barber, MA, MD, FRCP
Darcy Wooten
Darcy Wooten, MD, MS

Activity

Progress
1
Course Completed

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:

  • Switching with prior or unknown resistance
    • Data on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studies
    • The impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 study
    • A post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistance
    • Data from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184V
    • A retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS Cohort
  • Switching to long-acting ART
    • Guidance on candidates for LA CAB + RPV
    • Data on risk factors for virologic failure with LA CAB + RPV
  • Considering an ART switch after weight gain
    • Data on weight gain after ART initiation by ARV class and drug
    • Mean change in weight by sex at Week 96 in the ADVANCE study
    • DHHS guideline recommendations regarding weight gain with ART